Endothelial transcription factor EB protects against doxorubicin-induced endothelial toxicity and cardiac dysfunction

ABSTRACT: Doxorubicin (DOX), an effective chemotherapeutic drug for various cancers, has been demonstrated to induce cardiovascular toxicity in cancer survivors. Endothelial cell (EC) dysfunction is recognized to play a critical role in the onset and severity of cardiotoxicity associated with DOX. Transcription factor EB (TFEB), a master autophagy regulator, regulates cardiovascular homeostasis. In the present study, we aimed to test whether endothelial TFEB protects against EC damage after DOX treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE237200 | GEO | 2025/12/18

REPOSITORIES: GEO